12:51 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies.

FT819 cells are developed from an induced pluripotent stem cell (iPS cell) line and are engineered to lack a T cell receptor (TCR) and to dually target CD19 and Fc gamma receptor III (CD16; FCGR3).

While the two approved CAR T therapies -- Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) and Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) -- use a patient's own T cells for autologous therapies, several companies are developing off-the-shelf CAR Ts with iPS cells to create a consistent, uniform and renewable source of T cells (see BioCentury Innovations, Sept. 1, 2016).

Removing or inactivating TCRs is also important for an allogeneic therapy, as it prevents the cells from attacking tissues recognized as foreign in the recipient (see BioCentury Innovations, June 25, 2015).

In vitro functional studies showed that F819 elicits a cytotoxic T lymphocyte response to CD19 antigen challenge, as shown by the production of effector cytokines interferon (IFN) gamma, TNF alpha and IL-2. The cells also had more than 85% proliferation during differentiation.

In Burkitt's lymphoma and acute lymphoblastic leukemia cell lines, FT819 targeted cells in an antigen specific manner, as demonstrated by the lysis of CD19 positive cells, but not CD19 negative cells.

Fate dipped $0.39 to $11.15 on Monday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD